본문 바로가기
HOME> 논문 > 논문 검색상세

논문 상세정보

Archives de pédiatrie : organe officiel de la Société française de pédiatrie v.24 no.12, 2017년, pp.1336 - 1336   SCIE
본 등재정보는 저널의 등재정보를 참고하여 보여주는 베타서비스로 정확한 논문의 등재여부는 등재기관에 확인하시기 바랍니다.

Mycophenolic acid area under the curve is associated with therapeutic response in pediatric lupus nephritis

Godron, A. (Service de pédiatrie, SORARE, CHU de Bordeaux, France ) ; Decramer, S. (Service de néphrologie–rhumatologie pédiatrique, SORARE, CHU de Toulouse, France ) ; Fila, M. (Service de néphrologie–diabétologie pédiatrique, SORARE, CHU de Montpellier, France ) ; Guigonis, V. (Service de pédiatrie, SORARE, CHU de Limoges, France ) ; Tellier, S. (Service de néphrologie–rhumatologie pédiatrique, SORARE, CHU de Toulouse, France ) ; Scaon, M. (Service de pédiatrie, SORARE, CHU de Bordeaux, France ) ; Morin, D. (Service de néphrologie–diabétologie pédiatrique, SORARE, CHU de Montpellier, France ) ; Woillard, J.-B. (Service de pharmacologie–toxicologie, CHU de Limoges, France ) ; Saint-Marcoux, F. (Service de pharmacologie–toxicologie, CHU de Limoges, France ) ; Harambat, J. (Service de pédiatrie, SORARE, CHU de Bordeaux, France ) ;
  • 초록  

    Introduction Mycophenolic acid (MPA), the active metabolite of mycophenolate mofetil (MMF), is an effective treatment in lupus nephritis. Therapeutic drug monitoring studies of MMF suggest that area under the concentration-time curve (AUC) values of MPA of 30–45mg.h/L may be associated with better outcome in adults with lupus but data in children is scarce. Methods In this retrospective study, 27 children were treated with MMF for biopsy proven class III–IV–V lupus nephritis between 2009 and 2016. AUC of MPA was determined on the basis of sampling times at 20, 60, and 180minutes post-dose using a Bayesian estimator. In 25 children, AUC was performed within 6 months after kidney biopsy and MMF initiation. Treatment response at 6 months of MMF treatment was defined as follows: normal or improved GFR by 25% compared to baseline, 50% reduction of proteinuria resulting in a level Results In total, 62 AUC of MPA were analyzed [median 44mg.h/L (IQR 33–54)] in 27 patients. The findings indicate individual dose adaptation in 32 cases (52%) to achieve an AUC target of 30–60mg.h/L. At 6 months, 14/25 patients were defined as responders (56%) with a median AUC value of 49 [40–59] and 11/25 as non-responders (44%) with a median AUC value of 29 [24–38]. Patients with MPA AUC levels of >45, 30–45, and 45 was significantly associated with therapeutic response (OR 3.9, 95% CI 2.4–10.5, P Conclusion Therapeutic drug monitoring leading to individualize dosing may improve the efficacy of MMF. An AUC of MPA >45mg.h/L is associated with a better response rate and may be considered as a target value in paediatric lupus nephritis.


 활용도 분석

  • 상세보기

    amChart 영역
  • 원문보기

    amChart 영역

원문보기

무료다운로드
  • 원문이 없습니다.

유료 다운로드의 경우 해당 사이트의 정책에 따라 신규 회원가입, 로그인, 유료 구매 등이 필요할 수 있습니다. 해당 사이트에서 발생하는 귀하의 모든 정보활동은 NDSL의 서비스 정책과 무관합니다.

원문복사신청을 하시면, 일부 해외 인쇄학술지의 경우 외국학술지지원센터(FRIC)에서
무료 원문복사 서비스를 제공합니다.

NDSL에서는 해당 원문을 복사서비스하고 있습니다. 위의 원문복사신청 또는 장바구니 담기를 통하여 원문복사서비스 이용이 가능합니다.

이 논문과 함께 출판된 논문 + 더보기